Join
Login
Join
Login
"Where Everyone Has an MBA"
Tel: (612) 246-4616
Home
Financial Analysis
Companies
Industries
Glossary
About
Frequently Asked Questions
User Testimonials
Contact Us
Navigation
Home
Financial Analysis
Companies
Industries
Glossary
About
- Frequently Asked Questions
- User Testimonials
Contact Us
Cocrystal Pharma Inc - SIC # 2834 - PHARMACEUTICAL PREPARATIONS
Ticker
Exchange
SIC #
Website
Latest Ticker
COCP
Nasdaq
2834
https://www.cocrystalpharma.com/
Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:
Latest Headlines for Cocrystal Pharma Inc
Cocrystal Pharma to Present at the H.C. Wainwright Global Investment Conference
- May 18th, 2022 12:00 pm
COCP: Cocrystal Pharma Releases 2022 1st Quarter Results and Provides an Update on the Current Pipeline Programs
- May 12th, 2022 12:12 pm
Cocrystal Pharma Reports First Quarter 2022 Financial Results and Provides Updates on its Antiviral Development Programs and Milestones
- May 11th, 2022 12:00 pm
Cocrystal Pharma Collaborates with the National Institute of Allergy and Infectious Diseases to Evaluate COVID-19 Protease Inhibitors
- Apr 21st, 2022 12:00 pm
Cocrystal Pharma to Present at the Life Science Innovation Northwest 2022 Conference
- Apr 19th, 2022 12:00 pm
Cocrystal Pharma to Present at the Noble Capital Markets’ NobleCon18 Conference
- Apr 14th, 2022 12:00 pm
Cocrystal Pharma Posts Favorable Preliminary Data From Influenza A Antiviral Candidate Trial
- Apr 12th, 2022 3:01 pm
Cocrystal Pharma Reports Favorable Preliminary Data from Phase 1 Initial Cohorts with CC-42344, a Novel, Broad-Spectrum Influenza A antiviral
- Apr 12th, 2022 12:00 pm
10 Biotech Penny Stocks with Growth Catalysts
- Apr 6th, 2022 2:15 pm
We're Hopeful That Cocrystal Pharma (NASDAQ:COCP) Will Use Its Cash Wisely
- Mar 30th, 2022 6:57 pm
COCP: Cocrystal Pharma releases 2021 fiscal year results and provides an update on the current pipeline programs
- Mar 25th, 2022 11:30 am
Cocrystal Pharma Reports 2021 Financial Results and Provides Updates on Development Programs and Milestones
- Mar 23rd, 2022 8:05 pm
Cocrystal Pharma to Participate in the Maxim Group 2022 Virtual Growth Conference
- Mar 22nd, 2022 12:00 pm
Cocrystal Pharma Initiates Enrollment in Phase 1 Influenza A Study with Novel, Broad-Spectrum, Orally Administrated Antiviral CC-42344
- Mar 10th, 2022 1:00 pm
Cocrystal Pharma to Participate in Upcoming Investment Conferences
- Mar 3rd, 2022 1:00 pm
COCP: Cocrystal Pharma has secured funding to enter three clinical trials and fund planned operations through 2023
- Feb 24th, 2022 1:10 pm
Cocrystal Pharma To Develop Additional Two Antiviral Drug Candidates For COVID-19
- Jan 27th, 2022 5:22 pm
Cocrystal Pharma Selects Two Lead Antiviral Drug Candidates for its COVID-19 Oral Drug Program
- Jan 27th, 2022 1:00 pm
SomaLogic Announces Preliminary Revenue for Full Year 2021 Above Guidance Range
- Jan 11th, 2022 12:00 pm
SomaLogic Announces Appointment of Adam Taich as Chief Business Officer
- Jan 10th, 2022 9:10 pm
Scroll